CAF Accepting Applications for 2024- 2025 Medical Research Grants & Fellowships
The Cooley’s Anemia Foundation is accepting applications for medical research grants and fellowships in areas related to thalassemia. The awards are in three categories:
- Clinical Trials in Thalassemia Cell & Gene Therapy
- Clinical Research Application
- Research Fellowship Application
Details are as follows:
CLINICAL TRIALS IN THALASSEMIA CELL AND GENE THERAPY
The Cooley’s Anemia Foundation invites national and international applicants to apply for grants to facilitate clinical trials in Cell and Gene Therapy to advance a cure for thalassemia. Both phase I (safety) and phase II (efficacy) trials are eligible for support.
FUNDING AND CANDIDATE ELIGIBILITY
Applicants should state explicitly the status of their proposed trials; for example, whether the trial has been approved by the Food and Drug Administration (or equivalent processes at non-US sites) or whether review meetings at regulatory agencies have been scheduled.
Studies proposed for this RFA must be accompanied by a realistic timeline of progress to human trials. The Foundation recognizes that this timeline can be long. While the funds may be used toward any aspect of launching a human gene therapy trial, the Foundation will request careful documentation of other support of the investigator(s) and the project, and a thorough justification of the allocation of costs to various support mechanisms. This will best enable reviewers to assess feasibility of the proposed project. Examples of expenses allowed will include:
• Clinical-grade vector production and quality control
• Research subject assessments
• Late-preclinical studies and ex vivo studies on research subjects required for safety and efficacy assessments (including, but not limited to, evaluation of vector genome integration events, studies of transduction efficiency, studies of globin production by transduced hematopoietic stem cells from subjects)
• Patient care costs directly related to the study
• Research assistant or research nursing support.
Assurance must be given that adequate clinical and other facilities (including, where applicable, laboratory and vector production facilities) exist and are available to conduct the research project and, in case of investigations involving human subjects, a full human subject protection plan should be included as an appendix.
Total funding of up to $75,000 per year will be available (including indirect costs of 8%). With satisfactory evidence of progress and availability of funding grants may be renewed for a second year. Excluded from funding in this grant are lodging and other personal costs for research subjects to come to a treatment center.
Support for investigator effort may not exceed 10% of the current NIH salary cap.
Animal studies, if any, must be directly relevant to the specific proposed clinical trial.
The research may not be conducted at a for-profit laboratory.
Letters of reference are not required.
LETTER OF INTENT
Interested individuals are invited to submit a letter of intent by Monday, December 18, 2023, which includes the name of primary applicant, affiliation, and focus of proposal (not to exceed one paragraph). The completed application is due Monday, February 5, 2024. Both the letter of intent and the application should be emailed in PDF format to email@example.com. All applicants will be notified in June 2024 regarding the status of their funding.
ONGOING CLINICAL RESEARCH IN THALASSEMIA
The Cooley’s Anemia Foundation invites national and international applicants to apply for grants to support Ongoing Clinical Research projects in thalassemia.
The goal of this initiative is to support investigators from all disciplines and backgrounds (MD, RN, PhD, MPH, MSW or other disciplines) with their ongoing clinical projects to address one or more of the following areas impacting patients with thalassemia, including but not limited to: cardiac issues and iron overload; fertility, pregnancy and family planning; bone health, quality of life, psychosocial impact and/or burden of disease.
The stipends will be $50,000 annually with possibility of one-year renewal upon submission of a renewal application. Approval will be based upon determination of Satisfactory progress and availability of funds. Funds may be used for either salary or non-salary purposes, but the administrative cost is limited to 10% of the total amount granted.
This level of funding would be appropriate for support of innovative small-scale pilot studies, observational trials, or ancillary support for ongoing interventional studies (for example, support of a trainee joining an existing trial, or new biological endpoint analyses for an existing trial). In the case of ancillary studies, investigators should clearly document the support for the parent trial in their “other support” declarations.
Junior and senior faculty are eligible; fellows and trainees are not eligible. Investigators must interact directly with patients or patient-related data. Basic research, when included in this “Ongoing Clinical Research” program, must be related to a direct clinical focus of the grant application. Assurance must be given that adequate facilities exist and will continue to be available to conduct the research project and that the project has been reviewed and approved by the appropriate committee or governing body on human research. The research may not be conducted at a for-profit laboratory.
LETTER OF INTENT
Interested individuals are invited to submit a letter of intent by Monday, December 18, 2023, which includes the name of primary applicant, affiliation, and focus of proposal (not to exceed one paragraph). The completed application (including letters of reference, which must be submitted by the authors of the letters) is due Monday, February 5, 2024. Both the letter of intent and the application should be emailed in PDF format to firstname.lastname@example.org. All applicants will be notified in June 2024 regarding the status of their funding.
RESEARCH FELLOWSHIP GRANT APPLICATION
The Cooley’s Anemia Foundation invites national and international clinical and basic science investigators (postdoctoral or junior faculty) to apply for its prestigious fellowship program. Applications should be focused on the understanding or treatment of thalassemia or a complication that is related to thalassemia. The areas of interest include, but are not limited to, studies of globin gene regulation, globin gene transfer and expression, fetal hemoglobin production, hematopoietic stem cell research, bone marrow transplantation, iron chelation and iron overload, endocrine and cardiac disorders in thalassemia, and transfusion therapy and its complications.
Postdoctoral applicants must have adequate preceptorship and guidance by an experienced investigator. The sponsor of a postdoctoral fellow should be an investigator with adequate experience and at an institution with adequate research facilities. The application is expected to be the original work of the candidate but should reflect the close advice of the interested and involved sponsor. Applicants are encouraged to review the proposal with their mentor before submission in order to strengthen the application. Postdoctoral applicants must have an M.D., Ph.D., or equivalent degree, and cannot hold a faculty position.
Junior faculty applicants must have an M.D., Ph.D., or equivalent degree, and must have completed less than five years at the assistant professor level at the time the applications are due. Junior faculty members do not require sponsors.
Fellowships are awarded to the medical institutions where the research is to be undertaken; thus, each application must be approved by and administered through the appropriate administrative representative at the institution. Assurance must be given that adequate laboratory facilities exist and are available to conduct the research project and, in case of investigations involving human subjects, that the project has been reviewed and approved by the appropriate committee or governing body on human research. The research may not be conducted at a for-profit laboratory.
Preference will be given to applicants who have not yet achieved R-01 funding from the NIH.
Awards are for a one-year period, beginning July 1, 2024 and running through June 30, 2025 and are renewable for a second year upon application and consideration of progress made in the first year and the research plan for the second year. Continuation of fellowships for year two will also be contingent upon the availability of funds.
APPLICATION DUE DATE
Interested individuals are invited to complete and return applications in PDF format via email (email@example.com) no later than Monday, February 5, 2024. Letters of reference, which must be sent in separately, must also be received no later than Monday, February 5, 2024. All applicants will be notified in June 2024 regarding the status of their funding.
Please note the following:
• Fellowship awards are limited to a maximum of $50,000/year and may be renewable for a second year upon reapplication, as described above.
• Postdoctoral fellows may use award funds for salary support. Junior faculty applicants may use award funds for either salary or non-salary purposes. In both cases, the administrative cost is limited to 10% of the total amount granted.
• Payment of fellowship funds will be issued in quarterly checks, made out to the financial officer of the institution. The financial officer may establish an account from which junior faculty fellows may draw expenses allowed under the terms of the fellowship. Should the project not be initiated, should the project be stopped before completion or should the fellow either voluntarily or involuntarily leave the institution before the completion of the fellowship year, the institution agrees to return all unused funds for non-salary support during that award year and to forgo remaining quarterly payments.
• All publications resulting from Cooley’s Anemia Foundation sponsored fellowships should bear the statement: This study was supported by a grant from the Cooley’s Anemia Foundation.
• The Foundation and its Medical Advisory Board regret that it is not possible to provide detailed critiques to applicants.
1. Be sure to directly explain how your work will benefit patients with thalassemia
2. Make sure the scope and timeline of the proposed work fits with the timeframe of this award.
3. Make sure to show how the proposed work is distinct from other-funded research by your group.
4. Provide potential pitfalls and alternate approaches to each aim.
5. If innovative or novel work, or new techniques or procedures, are being proposed for which there are no or minimal preliminary data available, then there should be sufficient description to convince reviewers that this approach will be successful.
6. Please use Arial or Calibri font, size 11.